Besides traditional clinical management of HCC, the combination of atezolizumab and bevacizumab (atezo-bev) targeting, respectively, the immune checkpoint programmed death-ligand 1 (PDL1) and the angiogenic vascular endothelial growth factor (VEGF) has recently been approved as a first-line systemic treatment for unresectable or advanced HCC [11]. Here, VEGFA is linked to hepatocellular carcinoma.